Learn about our services
Learn about Retinal Diseases & more
Mid Atlantic Retina is an internationally recognized, pre-eminent retina practice in Pennsylvania, New Jersey and Delaware, delivering state-of-the-art, comprehensive patient care for over 40 years. Our practice is dedicated to the diagnosis and treatment of retina, vitreous and macula disorders, with the goal of improving the quality of life of our patients.
All of our doctors are:
Our 19 retina specialists utilize the most advanced therapies and surgical approaches, combined with an unfailing attention to consistency and detail, to provide the best treatment available.
On the Leading Edge of Technology - All of our offices have the latest diagnostic and therapeutic services.
We Keep Our Patients Informed - by providing information on common diseases in print and on our website.
Easily Accessible Offices - Our offices are easy to find, with multiple locations throughout the tri-state area.
Dr Allen Ho performed groundbreaking surgery at Wills Eye Hospital in Philadelphia implanting the Argus II Retina Prosthesis System. The patient was the first in our area to receive the device and is already exceeding expectations in her progress to see again with the retinal implant often described as the “bionic eye.” To read more about this go to
Patients can now view, save and print summaries of their medical records. If you are an existing patient and would like access to our new patient portal, please email firstname.lastname@example.org. Please include your name, DOB and the office that you receive treatment and you will receive instructions on how to access the portal within 24 hours.
We are pleased to announce James P. Dunn, MD has joined Mid Atlantic Retina.
Dr. Dunn will begin seeing patients on January 6, 2013 at our WillsEye location in Philadelphia as the new Director of The Uveitis Unit of the Retina Service at Wills Eye Hospital.
For more info on Dr Dunn please visit our physician page.
Mid Atlantic Retina is now participating in clinical trials looking at potential new therapies for patients with an advanced form of the dry type of age-related macular degeneration called geographic atrophy. For more information, please contact our Research Department at 215-928-3092.